Anika TherapeuticsSTU:AKP 63 Pretax Margin % is -16.28% as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 63/100 and a GF Value™ of €17.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Anika Therapeutics ranks worse than 75.31% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Anika Therapeutics Pretax Margin % Related Terms
Anika Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs LFCR, DERM, ASRT: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a Pretax Margin % of -16.28% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #720 out of 956 companies in the Drug Manufacturers industry, placing it in the top 75.3%.
Is Anika Therapeutics' Pretax Margin % too high?
Anika Therapeutics' current Pretax Margin % is -16.28%. Based on the distribution chart, Anika Therapeutics ranks #720 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Pretax Margin % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #720 out of 956 companies for Pretax Margin %. This places Anika Therapeutics in the lower half of its industry. The industry median Pretax Margin % is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Pretax Margin % is -16.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.74, compared to a current price of €13.80 — trading 22.2% below its estimated fair value. The current Pretax Margin % is -16.28%. Anika Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Pretax Margin % is -16.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of €13.80 is trading 22.2% below its estimated GF Value™ of €17.74.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AKP:
Pretax Margin %: -16.28%
GF Value™: €17.74 vs. price of €13.80 (22.2% below fair value)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
63GF Score
Get the complete analysis for STU:AKP
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
